Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, CA, 90095, USA.
Curr Rheumatol Rep. 2018 Feb 21;20(2):6. doi: 10.1007/s11926-018-0714-8.
There has been great interest in understanding why T regulatory cells (Tregs) are reduced in number and/or in function in several autoimmune diseases including systemic lupus erythematosus (SLE). Although research has provided some answers, there is still much to learn.
Recent investigations on the mechanisms responsible for the impairment of the Tregs in SLE have identified relevant abnormalities in cellular and molecular pathways that have been instrumental in the design of studies in animal models and in the development of pilot immunotherapeutic studies in lupus patients. We review the progress made in the field in the last 5 years, discussing the mechanistic studies, together with the preclinical and clinical works that are moving forward the understanding of the physiopathology of Tregs in SLE.
人们对于 T 调节细胞（Tregs）在包括系统性红斑狼疮（SLE）在内的几种自身免疫性疾病中数量减少和/或功能障碍的原因非常感兴趣。尽管研究已经提供了一些答案，但仍有很多需要学习的地方。
最近对导致 SLE 中 Tregs 受损的机制的研究已经确定了细胞和分子途径中相关的异常，这些异常对于设计动物模型中的研究和开发狼疮患者的初步免疫治疗研究至关重要。我们回顾了过去 5 年来该领域的进展，讨论了机制研究以及临床前和临床工作，这些工作推动了对 SLE 中 Tregs 病理生理学的理解。
